Emerging platinum(0) nanotherapeutics for efficient cancer therapy.

Platinum (Pt)-based chemotherapy has been necessary for clinical cancer treatment. However, traditional bivalent drugs are hindered by poor physicochemical properties, severe toxic side effects, and drug resistance. Currently, elemental Pt(0) nanotherapeutics (NTs) have emerged to tackle the dilemma. The inherent acid-responsiveness of Pt(0) NTs could help to improve tumor selectivity and alleviate toxic effects. Moreover, the metal nature of Pt facilitates the great combination of Pt(0) NTs with photothermal and photodynamic therapy and imaging-guided diagnosis. Based on recent important researches, this review provides an updated introduction to Pt(0) NTs. First, the challenges of traditional Pt-based chemotherapy have been outlined. Then, Pt(0) NTs with multiple applications of tumor theranostics have been overviewed. Furthermore, the combinations of Pt(0) NTs with other therapeutical modalities are introduced. Last but not least, we envision the possible challenges and prospects associated with Pt(0) NTs.

Evanescent Prostate Carcinoma, Case Report.

OBJECTIVE: To report the treatment and clinical monitoring in patients with prostatic evanescent carcinoma at Hospital Carlos Andrade Marin. METHODS: We reviewed the medical records of 148 patients undergoing by robot-assisted radical prostatectomy in Carlos Andrade Marin hospital. The cases reported between January 2016 to December 2018. The diagnosis was carried by taking a transrectal prostate biopsy with 12 cylinders. This samples are studied by the pathologist who reviews the radical prostatectomy surgery. RESULTS: Three patients had prostatic evanescent carcinoma, which those cases showed Gleason 6 (3+3) prostate cancer. Two received neoadjuvant hormone therapy and the other patient presented minor tumor invasion in 1 out of 12 cylinders used during the biopsy. In the three cases, after the sample analysis, there was no residual tumor evidence. Therefore, they were classified as pT10. CONCLUSIONS: In this study, the results obtained from the patients studied presents the incidence of prostatic evanescent carcinoma is 2%. The combination of these different factors such as clinical status, preoperative PSA, number of positive cylinders and the invasion percentage, additionally to the usage of neoadjuvant hormone therapy prior the radical prostatectomy can help to predict evanescent carcinoma of the prostate.

Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.

Purpose: Absence of tumor in the final histopathology after radical cystectomy (RC) is a rare but potentially favorable outcome. Therefore, we aimed to analyze outcomes and prognostic factors of patients with urothelial carcinoma (UC) undergoing RC and T0 in the final histology without neoadjuvant chemotherapy at a high-volume academic center. Patients and Methods: We retrospectively analyzed patients undergoing RC for pure UC between 2004 and 2020. Cancer-specific survival (CSS) and overall survival (OS) were calculated using Kaplan-Meier analysis and group comparison by Log rank test. Potential prognostic factors were analyzed using univariate Cox regression models. Results: A total of 1051 patients with UC underwent RC. 72 patients (6.7%) showed pT0 in the final histology. Across all T-stages, 5-year CSS was significantly different with 88% for pT0, 80% for pTa/pTis, 78% for pT1, 76% for pT2, 51% for pT3 and 27% for pT4 in our cohort (p=0.001). Neither instillation therapy (HR 0.31, 95% CI 0.07-1.43), number of TURB prior RC (HR 1.47, 95% CI 0.25-6.18), use of photodynamic diagnostics (PDD) (HR 0.64, 95% CI 0.14-3.02), performing a second resection (HR 0.87, 95% CI 0.27-2.86), muscle-invasive disease prior RC at any TURB (HR 0.7, 95% CI 0.2-2.39) or muscle-invasive disease in the TURB prior RC (HR 1.0, 0.31-3.29) were associated with CSS in univariate analysis. Conclusion: pT0 reveals a survival benefit in patients undergoing RC for UC and therefore presents a distinctive tumor entity. As clinical and cystoscopic characteristics do not improve patient stratification, further research is warranted to define risk groups in this specific tumor entity.

New insight into the mechanism of Pt(0)-catalyzed hydrosilylation reaction of (CH3)3SiH with CH2CHSi(CH3)3.

The non-catalytic hydrosilylation reaction has much high activation energy due to large differences in the energy of HOMO-LUMO pairing and restriction of the orbital symmetry overlap. For Pt(0)-catalytic hydrosilylation, the electronic structure of Me3SiH has been modified by the oxidative addition of Pt(0). It not only narrows down the energy differences between the bonding orbitals but also improves the orbital overlap symmetry, leading to the effective decrease of the activation energy. The trouble for the Pt(0)-catalytic hydrosilylation is the formation of the majority of the Pt-containing intermediates. Because they are fallen into the deep potential-energy, the reductive eliminations are energetically prohibitive, which is the essence of Pt-contamination. The reductive elimination can be achieved with the ligand exchange method, and the energy barrier can be tuned by suitable ligands.

Evanescent Prostate Carcinoma, Case Report

Objective: To report the treatment and clinical monitoring in patients with prostatic evanescent carcinoma at Hospital Carlos Andrade Marin. Methods: We reviewed the medical records of 148 patients undergoing by robot-assisted radical prostatectomy in Carlos Andrade Marin hospital. The cases reported between January 2016 to December 2018. The diagnosis was carried by taking a transrectal prostate biopsy with 12 cylinders. This samples are studied by the pathologist who reviews the radical prostatectomy surgery. Results: Three patients had prostatic evanescent carcinoma, which those cases showed Gleason 6 (3+3) prostate cancer. Two received neoadjuvant hormone therapy and the other patient presented minor tumor invasion in 1 out of 12 cylinders used during the biopsy. In the three cases, after the sample analysis, there was no residual tumor evidence. Therefore, they were classified as pT10. Conclusions: In this study, the results obtained from the patients studied presents the incidence of prostatic evanescent carcinoma is 2%. The combination of these different factors such as clinical status, preoperative PSA, number of positive cylinders and the invasion percentage, additionally to the usage of neoadjuvant hormone therapy prior the radical prostatectomy can help to predict evanescent carcinoma of the prostate (AU)

Objetivos: Reportar la experiencia del Hospital Carlos Andrade Marín en el tratamiento y seguimiento de pacientes con cáncer de próstata evanescente.Materiales y Métodos: Se ha estudiado las historiasclínicas de 148 pacientes que se realizaron prostatectomíaradical asistida por robot en el Hospital Carlos AndradeMarín en el periodo enero 2016 hasta diciembre 2018, eldiagnostico se realiza mediante toma de biopsia prostáticatransrectal con toma de 12 cilindros, los cuales son estudiados por el mismo medico patólogo que revisa la piezaquirúrgica de prostatectomía radical.Resultados: Se identifican tres casos de carcinomade próstata evanescente, los cuales presentan carcinoma depróstata Gleason 6 (3+3), dos reciben terapia neoadyuvantehormonal y uno presenta escasa invasión tumoral en 1/12cilindros de biopsia prostática (cáncer de próstata diminuto). En los tres casos después del análisis de las piezasquirúrgicas no se evidencia tumor residual por lo que se loscataloga como pT0.Conclusiones: En nuestra experiencia la incidenciade carcinoma de próstata evanescente es del 2% en elgrupo de pacientes estudiados. La combinación del estadio clínico, PSA preoperatorio, numero de cilindros positivos y el porcentaje de invasión de los mismos como el usode neoadyuvancia previo a la prostatectomía radical puedeayudar a predecir el fenómeno de carcinoma de próstata evanescente (AU)

Uniform platinum nanoparticles loaded on Universitetet i Oslo-66 (UiO-66): Active and stable catalysts for gas toluene combustion.

Highly dispersed Pt nanoparticles supported UiO-66 catalysts were successfully prepared by the incipient wetness impregnation method. Their thermal catalytic performances were evaluated by toluene degradation. The physicochemical properties of the samples were characterized using a series of characterization methods. The catalytic activity of catalysts remained essentially unchanged in the high weight hourly space velocity, stability and water resistance test, which also indicated good catalytic performance. In the reusability test, the catalytic performance was found to be enhanced after the reaction, because of the catalyst might follow a Pt0-PtO synergistic catalytic mechanism (similar to Mars-van Krevelen mechanism) and there was a phase transition between Pt0 and PtO during the reaction. Firstly, the toluene adsorbed on the catalyst surface was oxidized by the activated lattice oxygen of the PtO. Then, consumption of oxygen atoms led to formation of oxygen vacancies, and finally the molecular oxygen adsorbed by Pt0 was activated and passed to the PtO to supplement the oxygen vacancies, forming a redox cycle. In addition, the possible catalytic oxidation mechanism of toluene was also revealed.

Highly Efficient Catalysts of Bimetallic Pt-Ru Nanocrystals Supported on Ordered ZrO2 Nanotube for Toluene Oxidation.

ZrO2 nanotube arrays and their supported bimetallic platinum and ruthenium (PtxRuy/ZrO2; x + y = 1 mmol %, x/y = 1:0, 0.9:0.1, 0.8:0.2, 0.7:0.3, 0.5:0.5, 0:1) nanocomposites were fabricated by employing SBA-15-OH as a hard template and an impregnation method, respectively. A controlled ordered nanotube array structure formed from the fabricated catalysts, and it showed a good performance for toluene oxidation. The specific physicochemical properties of the catalysts were examined through various analytical means. The PtxRuy/ZrO2 possessed a high surface area, and the Pt-Ru nanoparticles were dispersed uniformly on the ZrO2 nanotube surface. The Pt0.7Ru0.3/ZrO2 catalyst performed best among all of the samples, with T90% and T100% (temperatures for 90 and 100% conversion of toluene) of 140 and 160 °C, respectively, at a weight hourly space velocity of 36 000 mL/(h·g). These bimetallic catalysts exhibit excellent characteristics for toluene oxidation, such as higher turnover frequencies and lower apparent activation energy (Ea) values, which probably result from the synergistic effect of the Pt-Ru noble metals that leads to a high reducibility and oxygen adsorption capacity. The excellent activity, stability, and economics of the Pt0.7Ru0.3/ZrO2 catalyst allow for its application in toluene removal.

Diferrocenyl Thioketone: Reactions with (Bisphosphane)Pt(0) Complexes-Electrochemical and Computational Studies.

Diferrocenyl thioketone reacts smoothly with (bisphosphane)Pt(0) complexes in toluene solution at room temperature yielding 1:1 adducts identified as ferrocenyl (Fc) functionalized platinathiiranes. Their structures were unambiguously confirmed by means of spectroscopic methods as well as by X-ray diffraction analysis. A unique, ferrocene-rich platinathiirane, bearing three Fc-units, was prepared starting with [bis(diphenylphosphino)ferrocene] Pt(0(η2-norbornene). For comparison, a similar platinathiirane with one Fc-unit was obtained from the reaction of the latter complex with thiobenzophenone. Quantum-chemical calculations were carried out to describe the bonding pattern and frontier molecular orbitals of the ferrocene-rich platinathiirane complexes. These calculations confirmed that the C=S bond loses its formally double-bond character upon complexation (bisphosphane)Pt(0). Cyclic voltammetry measurements were performed to characterize the obtained platinathiiranes in CH2Cl2 solutions. For comparison, the cyclic voltammogram for diferrocenyl thioketoneas a mixed-valent (FeII-FeIII) compound was also recorded and analyzed. The results point out to a diffusion controlled electrode process in case of differocenyl thioketone and mixed diffusion and adsorption controlled electrode process in the case of the studied platinathiiranes.

Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population-based study.

BACKGROUND: The incidence of pT0 prostate cancer (CaP) at radical prostatectomy (RP) is extremely rare. We performed the first population-based analysis of pT0 CaP at RP. METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2015), we tested for clinical and pathological characteristics according to pT0 vs. non-pT0 CaP and included a multivariable logistic regression model. RESULTS: pT0 was identified in 358 (0.2%) out of 160,532 clinically localized RP patients. The majority of pT0 patients presented with initial prostate-specific antigen (PSA) <10 ng/ml (82.4%), harboured biopsy Gleason score (GS) 6 (69.8%) and cT1 disease (78.1%). Nonetheless, pT0 was identified in 13 (3.6%) patients with PSA ≥20 ng/ml, in 69 (19.3%) patients with biopsy GS ≥7 and in 78 (21.8%) patients with ≥cT2 disease. In a subset of patients with available number of biopsy cores, pT0 was identified in 34 (33.3%) patients with ≥2 positive biopsy cores. Age, race, marital status, hospital region, population density, PSA, as well as number of biopsy cores did not discriminate between pT0 and non-pT0 cases. Analyses according to annual rates (2004-2015) of pT0 did not vary between the years (0.2%-1.6%, estimated annual percent change: -1.6%, P = 0.3). Neither did the rates vary according to geographic region. CONCLUSIONS: pT0 at RP is very rare. Even though, most pT0 patients have low PSA, low clinical stage, low biopsy GS, and only one positive biopsy core, those with more aggressive characteristics can still harbour pT0 at RP.

Resultados oncológicos en pacientes con cáncer de vejiga pT0 posterior a cistectomía radical / Oncological outcomes of Patients with pT0 Bladder Cancer after Radical Cystectomy

Introducción: El estadío pT0 del cáncer de vejiga implica la ausencia de enfermedad en la pieza de cistectomía radical (CR). El objetivo de este estudio es describir los resultados oncológicos de los pacientes con estadío pT0 posterior a CR por carcinoma urotelial de vejiga. Materiales y métodos: Estudio retrospectivo de pacientes sometidos a CR por cáncer de vejiga, en una sola institución, sin neoadyuvancia, entre junio de 2005 y julio de 2013. Se incluyeron aquellos pacientes con diagnóstico histológico de estadío pT0 pN0. Se estimó la sobrevida global, sobrevida cáncer-específica y sobrevida libre de recidiva con el método de Kaplan-Meier. Resultados: De 254 pacientes cistectomizados, 17 presentaron estadío pT0 pN0 (6,7%). La mediana de edad fue 67 años (rango 49-85), 15 pacientes fueron hombres (88%). Los resultados patológicos posterior a resección transuretral de vejiga (RTUv) fueron 17% pT1 (n=3) y 83% pT2 (n=14). La mediana de tiempo entre RTUv y CR fue 60 días (rango 30- 95). Al 41% se le realizó derivación urinaria tipo Bricker y al 59%, una neovejiga. La mediana de estadía hospitalaria fue 8 días (rango 6-44). Se evidenció adenocarcinoma de próstata en 4 pacientes. La mediana de ganglios resecados fue 6 (rango 2-17). Ningún paciente recibió adyuvancia. La mediana de seguimiento fue 69 meses (rango 5-120). Un paciente presentó recidiva uretral a los 72 meses de la CR. La sobrevida cáncer-específica fue 100%, la sobrevida libre de recaída a 5 años fue 83,3% (intervalo de confianza [IC] de 95%: 53,5-100) y la sobrevida global a 5 años fue 82,4% (IC 95%: 64,7-100). Conclusión: El estadío pT0 del cáncer de vejiga presenta resultados oncológicos más favorables que los estadíos más avanzados. Sin embargo, la posibilidad de recurrencia existe, por lo que no se debe discontinuar el seguimiento de estos pacientes (AU)

Introduction: There are cases in which there is no evidence of disease in the radical cystectomy (RC) specimen (pT0 stage). The purpose of this study is to evaluate oncological outcomes of patients with pT0 bladder cancer after RC, in a single institution, without neo-adjuvant therapy. Materials and methods: Patients who underwent radical cystectomy from June 2005 to July 2013 were reviewed retrospectively. All patients had history of bladder urothelial carcinoma, treated with transurethral resection of the bladder (TURB) and confirmed with pathological analysis. Study variables included TURB pathology, time to RC, and pathologic features. Overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS) were estimated. Results: RC was performed on 254 patients; 17 patients (6.7%) had pT0N0 stage. Median age was 67 years (range 49-85 years); 15 patients were male (88%). TURB pathology specimens were 17% pT1 (n=3), and 83% pT2 (n=14). Median time between TURB and RC was 60 days (range 30-95). Seven patients (41%) received an ileal conduit, and ten patients (59%) received a neobladder. Median hospital stay was eight days (range 6-44). Prostate adenocarcinoma was found in four (23%) patients. Median resected lymph nodes were six (range 2-17). No patients received adjuvant chemotherapy. Median follow-up was 69 months (range 5-120 months). One patient had a urethral relapse 72 months after RC. There was no cancer-specific mortality. RFS at 5 years was 83.3% (confidence interval [CI] 95%: 53.5-100); OS at 5 years was 82.4% (CI 95%: 64.7-100). Conclusion: pT0 stage after radical cystectomy shows more favorable oncologic outcomes than higher stages. However, cancer recurrence was found in a low number of patients, thus, patient follow-up should be maintained (AU)

Clinicopathologic features and prognosis analysis for stage pT0 prostate cancer after radical prostatectomy / 中华泌尿外科杂志

Objective To analyze the clinical and pathological characteristics and prognosis of stage pT0 prostate cancer patients after radical prostatectomy.Methods From November 2004 to May 2017,eight patients who underwent radical prostatectomy and postoperatively diagnosed with pT0 were retrospectively evaluated.The patients aged 63-75 years (mean 69.1 years),with PSA 2.26-14.10 ng/ml(mean 6.10 ng/ml),prostate volume 30.3-72.1 ml (mean 52.1 ml).Exclusion criteria included patients undergoing neoadjuvant hormone therapy or TURP before the operation.Stage pT0 prostate cancer was defined as no evidence of residual tumor in radical prostatectomy specimen from the patient in whom biopsy-proven prostate carcinoma was histologically diagnosed.The clinical and pathological data were reviewed and follow-up was performed for stage pT0 prostate cancer patients.Biochemical progression was defined as postoperative PSA greater than 2 ng/ml for twice.The patients were followed-up.Results Eight patients (1.1％) were postoperatively diagnosed with prostate cancer of pT0 stage.After radical prostatectomy specimen was reexamined by an uropathological expert,small residual tumor(2mm) was found in left peripheral zone of the prostate in one patient.The average follow-up duration was 75 months for this 8 pT0 patients.One patient died of pulmonary embolism after 5 days of the surgery.No patient had evidence of biochemical progression.No biochemical recurrence survival rate and cancer-specific survival rate was 100％ (7/7) and overall survival rate was 87.5％ (7/8) for pT0 prostate cancer patients.Conclusions For patients who were biopsy-proven prostate cancer without neoadjuvant hormone therapy,stage pT0 was a rare pathological phenomenon.Those patients had a very favourable oncological prognosis.